Two neighboring rural counties, two dispatch centers, one common platform supporting more than 900 square miles of mountainous terrain

NORTH LITTLE ROCK, Ark., Oct. 17, 2026 /PRNewswire/ -- Caliber Public Safety announced that Highland County and Bath County, Virginia went live on Caliber Hosted CAD on Tuesday, October 6, with both counties operating within a shared hosted environment. The arrangement gives each county its own dispatch operation while placing both on a common platform, creating a practical foundation for coordination between two neighboring jurisdictions.

For rural agencies, interoperability is usually a question of what happens when an incident crosses a county line. Mutual aid is routine in this part of western Virginia, where Highland County covers roughly 416 square miles with about 2,300 residents, and Bath County covers more than 500 square miles with about 4,100 residents. Together, the two counties serve a largely forested and mountainous service area with a small number of dispatchers and responders on any given shift.

The shared tenant approach addresses that directly. Each county retains the configuration, workflows, and local control it needs to run its own center. Both counties work from the same underlying platform, which removes the technical barriers that normally sit between separate CAD systems in adjacent jurisdictions.

"Two counties sharing one hosted CAD environment is not something you see often in rural public safety, and it took real coordination between both counties and our teams to get there," said Michael Sturgeon, Senior Project Manager at Caliber Public Safety. "What matters is what the dispatchers and responders have now. Each county runs its own center the way it needs to, and neither one is working in isolation anymore."

Capabilities Delivered

Highland County, which joined the Caliber CAD customer base with this project, is now operating Hosted CAD with integrated mapping and CJIS query, along with Google Places address validation and a LinX interface for regional information sharing. The county also uses Caliber's Online RMS for sworn and non-sworn personnel. For dispatchers covering a county with one of the highest mean elevations east of the Mississippi River, verified addressing and immediate access to criminal justice data reduce the guesswork that slows down a call.

Bath County is operating Hosted CAD with mapping and CJIS query, plus interfaces to PulsePoint, RapidSOS with alerts. The RapidSOS connections put caller location and device data in front of the dispatcher at the start of the call, which matters in terrain where a caller may not be able to describe where they are. The PulsePoint interface extends cardiac arrest notifications to trained citizens and off-duty responders nearby, a meaningful addition in a county where response distances are long.

A Migration, Not Just an Implementation

Bath County has been a Caliber premise CAD and Online RMS customer for years. As part of this project, the county moved its premise-based system onto Hosted CAD, and Caliber completed a data conversion to bring the historical CAD databases forward into the new environment.

That piece is often the sticking point for agencies considering a move off a premise system. Years of call history, incident records, and master index data represent case continuity, state reporting obligations, and institutional knowledge. Data conversion is a formal, structured component of every Caliber implementation, with Caliber's team managing the technical transformation, validation, and loading so that historically critical records carry over intact.

Caliber products are hosted at Nlets, the International Justice and Public Safety Network, and meet FBI CJIS policies, standards, and guidelines. The facilities include multi-site hot backup disaster recovery and redundant network paths to key state and federal entities.

Project Teams

The go-live required coordination among both counties and Caliber's Professional Services, Deployment, Training, Engineering, and Support teams. Caliber congratulates the public safety professionals of Highland County and Bath County on a successful implementation and looks forward to a fruitful partnership.

About Caliber Public Safety

Caliber Public Safety provides integrated technology solutions for law enforcement, fire/EMS, corrections, and 911 communications agencies. The Caliber platform includes CAD, Mobile, Online RMS, and JailTracker, all built by and for public safety professionals. With a focus on reliability, interoperability, and ease of use, Caliber serves hundreds of agencies across the country, helping first responders spend less time on technology and more time serving their communities.

SOURCE Caliber Public Safety

Share this article

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

- 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs

- Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis

- New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented

NORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

- Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.

- Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.

Upadacitinib in the Real World: New Insights from Clinical Practice

- Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.

- A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.

Additional Findings on Risankizumab Subcutaneous Induction in CD

- Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.

aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.

bDefined as endoscopic subscore = 0.

cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.

dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.

eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

About SKYRIZI®

SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

BEIJING, Oct. 16, 2026 /PRNewswire/ -- The grand event of the global ice and snow industry, the World Winter Sports Expo 2026 (WWSE 2026), was held in Beijing on October 15. As an important legacy of the Beijing 2022 Olympic Winter Games, this Expo aligns with China's "15th Five‑Year Plan" directives for the ice and snow industry. Its core mission is to expand the ice and snow economy, cultivate new productive forces in the sector, and promote deep integration of culture, sports, and tourism. It brought together representatives from government authorities, industry leaders, cultural‑tourism‑sports experts, outdoor film and media creators, and institutions across the entire value chain. Focusing on three strategic directions, upgrading the ice and snow industry, deepening culture‑sports‑tourism integration, and empowering the outdoor economy through technology, this WWSE features an opening ceremony, a main conference, multiple parallel sessions, and special thematic events. Together, these form a high‑end platform for achievement showcase, intellectual exchange, business matchmaking, and resource aggregation, aimed at driving higher‑quality growth for China's ice and snow and outdoor sectors.

Positioned at the pivotal starting point of a new decade of development, this Expo delivers a comprehensive upgrade: internationalization continues to reach new heights, the entire ice and snow value chain is presented in a coordinated way, scientific and technological innovation empowers the sector, ice and snow destinations pursue diversified growth, youth engagement in ice and snow sports advances through systematic promotion, forum agendas focus on niche tracks, the Ice and Snow Carnival offers a whole-scenario experience, industry-academia-research collaboration and industry services assume a stronger leading role, and a range of measures inject fresh vitality into the ice and snow economy.

At the Opening Ceremony of the WWSE 2026 and Global Ice and Snow Industry Summit, more than 200 domestic and international dignitaries gathered to witness the Expo's launch. Among them were: Yu Zaiqing, Honorary Member of the International Olympic Committee and Vice President of the Chinese Olympic Committee; Yue Li, Acting District Mayor of Shijingshan and Deputy Secretary of the CPC Shijingshan District Committee of Beijing Municipality; Tong Zhao, Deputy Secretary-General and Office Director of the Liaoning Provincial Organizing Committee of the 15th National Winter Games; Zhu Dongfang, President of Asia Data Group; Franz Roessler, Commercial Counsellor at the Austrian Embassy in Beijing, and Head of the ADVANTAGE AUSTRIA Beijing; Hong Ping, Vice President of Beijing Sport University; Wang Dong, Deputy Director of the Liaoning Provincial Bureau of Sports, and Full-Time Deputy Director of the Competition Department of the Liaoning Provincial Organizing Committee for the 15th National Winter Games; Gao Zhaoyi, Member of the Leading Party Members Group and Director of the Sports Bureau of the Xinjiang Uygur Autonomous Region; Zhan Wei, Vice Mayor of the Fushun Municipal People's Government of Liaoning Province; Zhang Li, Co-President of Asia Data Group; Li Jianrou, Olympic Short Track Speed Skating Champion; Wang Bingyu, World Curling Champion; Zhao Nannan, World Short Track Speed Skating Champion; and Jiang Yiyi, Deputy Secretary of the Party Committee and Dean, School of Leisure Sports and Tourism, Beijing Sport University.

Opening Ceremony Held in Grand Style, Uniting All Partners to Chart the Industry's Blueprint Together

On the morning of October 15, the Opening Ceremony of the WWSE 2026 and Global Ice and Snow Industry Summit was held. Closely following the development direction for the ice and snow industry set out in China's 15th Five-Year Plan, the Opening Ceremony took on the important missions of policy promotion, industry gathering, international dialogue and achievement release, and built a bridge for high-level dialogue among government agencies, international sports organizations, industry companies and research, cultural and tourism institutions. Serving both as a concentrated showcase of China's achievements in the ice and snow industry and as a key platform for the industry to assess trends, connect with resources and build consensus, it injected strong momentum into the innovative development of the ice and snow and outdoor industries throughout the year.

At the Opening Ceremony, Honorary Member of the International Olympic Committee and Vice President of the Chinese Olympic Committee, Yu Zaiqing, delivered the opening address. 11 years ago, he said, the Expo was launched alongside Beijing's successful bid to host the Olympic Winter Games. Today, it has grown into one of the world's leading platforms in the ice and snow industry. It has driven China's shift from being a major consumer market to becoming a powerful industry leader, and the Winter Olympics legacy continues to provide momentum. On this basis, he called for upholding the Olympic spirit of "Together", deepening international cooperation on ice and snow, and advancing the intelligent, green and international development of the industry.

Yue Li, Acting District Mayor of Shijingshan and Deputy Secretary of the CPC Shijingshan District Committee of Beijing Municipality, then delivered an address. The Expo has grown into an influential international ice and snow event and serves as an important link for Shijingshan to connect with global ice and snow resources. As a host district of the Beijing Olympic Winter Games, Shijingshan has continued to revitalize the Winter Olympic legacy, build a four-season events matrix, and promote the integrated development of ice and snow and the events economy. He expressed the hope to share the Winter Olympic legacy and jointly explore the blue ocean of the ice and snow industry with all parties, so as to help advance the global ice and snow economy.

As the representative of this year's Guest Province of Honor, Tong Zhao, Deputy Secretary-General and Office Director of the Liaoning Provincial Organizing Committee of the 15th National Winter Games, delivered an address at the Opening Ceremony. She noted that Liaoning has deep ties with WWSE, and this year it is drawing on its status as Guest Province of Honor to present the province's ice and snow resources, industrial achievements and cooperation opportunities. With the 15th National Winter Games set to be held in Liaoning in 2028, it is expected to become the first in China to have hosted both the National Games and the National Winter Games. Liaoning looks forward to learning from international experience through the Expo and extended a warm invitation to all parties to join it for the 15th National Winter Games.

Christophe Dubi, Olympic Games Executive Director of the International Olympic Committee, then delivered an address by video. He reviewed Beijing 2022's experience of hosting the Games across multiple competition zones and contrasted it with Milano Cortina 2026's approach of tailoring the Games to local conditions, proposing that the Games should adapt to the host rather than the host adapting to the venues. He also affirmed the value of forward-looking planning for Olympic venues and their post-Games reuse, and noted that climate change is confronting the industry with challenges ranging from snow resources to energy consumption, making the transformation of the ice and snow industry all the more urgent. He expressed the hope that those engaged in the industry would work together to explore a sustainable development path for ice and snow sports.

In the keynote speech session, Hong Ping, Vice President of Beijing Sport University, and Former Deputy Director of the Winter Sports Management Center, General Administration of Sport of China, shared his insights under the theme of "Reflections and Explorations on the High-Quality Development of the Ice and Snow Industry — Trend Transformation, Intelligent Manufacturing, and Safety Governance". He noted that China's sports market is huge in scale and that new indoor ice and snow formats are rising rapidly, with ice and snow consumption becoming an important lever for boosting domestic demand, yet the industry's development still falls short in several respects. He therefore called for a people-centered approach, building a coupled "human–machine–environment" mega-system and developing fifth-generation ski products that are science-based, smart, green, healthy and safe. This will drive the high-quality development of the ice and snow industry through demand pull and scientific and technological innovation.

In their addresses, Alexander Ospelt, President of International Ski and Snowboard Federation (FIS); Olle Dahlin, Honorary President of the International Biathlon Union (IBU); and Einars Fogelis, President of the International Luge Federation (FIL), conveyed a shared message from the global ice and snow industry: staying open and collaborative, and working together for the industry's development. They affirmed that the Expo has built a platform for global ice and snow exchange and cooperation, recognized the rapid growth of ice and snow sports in Asia, shared the outcomes of Milano Cortina 2026, and highlighted the importance of sustainable development in ice and snow sports. Looking ahead, they expressed the hope of using the Expo to deepen cross-regional and cross-generational exchanges and to jointly advance the continued prosperity of winter sports.

In the report release session, Co-President of Asia Data Group Zhang Li launched the "Report on China's Winter Sports Industry Development (2026)".

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Navan, Inc. ("Navan" or the "Company") (NasdaqGS: NAVN).

Navan, headquartered in Palo Alto, California, provides booking and expense management software for business travelers. On or about October 31, 2025, Navan conducted its initial public offering (the "IPO" or "Offering"), selling 36,924,406 shares of common stock to the investing public at $25 per share. The registration statement and prospectus issued in connection with the IPO (the "Offering Documents") touted that Navan's business had "experienced rapid growth," including year-over-year revenue growth of 33%, Gross Booking Volume growth of 32%, and a usage yield of approximately 7% in each of fiscal years 2024 and 2025. However, the Offering Documents allegedly failed to disclose that this growth was increasingly dependent on escalating sales and marketing spending: in the quarter ending October 31, 2025, the very day of the IPO, Navan's sales and marketing expenses rose to approximately $95 million, a 39% increase over the $68.5 million spent in the prior quarter.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws. That litigation remains ongoing.

KSF's investigation is focusing on whether Navan's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Navan shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3608 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-navn/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3608

1100 Poydras St., Suite 3200

New Orleans, LA 70163

SOURCE Kahn Swick & Foti, LLC

Share this article

VANCOUVER, BC, Oct. 16, 2026 /PRNewswire/ -- Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) will hold a conference call on Monday November 16th, 2026 at 8:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to review third quarter 2026 operating results.

The live call can be accessed by dialing +1-833-821-2814 (Canada/US toll free). Alternatively, a live webcast can be accessed through a link on Ballard's homepage (www.ballard.com), in the 'Latest News' section or by clicking here: Q3 Webcast.

Following the call, a link to the webcast will be available in the 'Investor Hub' area of the 'Investors' section of Ballard's website (www.ballard.com/investors).

About Ballard Power Systems

Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) is a global leader in zero-emission hydrogen energy solutions and an integrated Energy-as-a-Service (EaaS) provider. Together, with its wholly owned subsidiary, GeoPura Ltd., Ballard delivers turnkey, vertically integrated hydrogen ecosystem solutions spanning hydrogen production, logistics, refuelling, zero-emission fuel cell engines, and stationary Hydrogen Power Units.

Ballard powers critical off-grid, stationary applications - including construction, events, film sets, healthcare, defense, temporary power infrastructure, and supplies fuel cell engines for heavy-duty mobility applications such as bus, rail, and marine. With an EaaS model, combined with cutting-edge technology across the hydrogen value chain, Ballard decarbonizes mission-critical operations worldwide. To learn more about Ballard, visit www.ballard.com.

Further Information

Sumit Kundu –Investor Relations,+1.604.360.9714 or [email protected]

SOURCE Ballard Power Systems Inc.

Share this article

LAKELAND, Fla., Oct. 16, 2026 /PRNewswire/ -- Florida Southern College honored distinguished alumnus Lt. Gen. Donald L. Kerrick on Friday, Oct. 16, with the dedication of the College's Army ROTC building in his name. The celebration continues Saturday, Oct. 17, with the second annual Lt. Gen. Donald L. Kerrick JROTC Raider Competition, welcoming 22 high school teams from across Florida to Florida Southern.

Through a generous gift, Kerrick is supporting significant renovations and equipment upgrades for Florida Southern's Army ROTC Moccasin Battalion. The investment will enhance training facilities and resources for future military officers and leaders. In recognition of his generosity and distinguished service, the facility will be named the Lt. Gen. Donald L. Kerrick Building.

"Lieutenant General Kerrick represents the very best of Florida Southern College and the extraordinary impact our graduates can have on the world," said Dr. Jeremy Martin, president of Florida Southern College. "From his distinguished service to our nation at the highest levels of military and civilian leadership to his continued investment in our students, his life exemplifies the values of leadership, character and service that define our institution."

A 1971 graduate of Florida Southern College, Kerrick was commissioned as a second lieutenant in the U.S. Army upon graduation. His distinguished military career included combat assignments in Southeast Asia and Operation Desert Storm, as well as senior leadership positions in military and national security operations. In 2000, he was appointed Deputy National Security Advisor to the President of the United States. He also served on the U.S. Balkans Peacekeeping Delegation, which helped negotiate the historic Dayton Peace Agreement ending the war in Bosnia.

Among his numerous military honors are the Defense Distinguished Service Medal, Legion of Merit and Bronze Star Medal. Florida Southern has also recognized Kerrick with its Distinguished Alumni Achievement and an honorary Doctor of Diplomacy degree.

The celebration continues Saturday as the College's Army ROTC Moccasin Battalion hosts the second annual Lt. Gen. Donald L. Kerrick JROTC Raider Competition. The event will bring together 22 high school teams to compete in five challenges testing physical endurance, discipline, leadership and teamwork, including a 5K run, One Rope Bridge, Cross Country Rescue, Tire Flip and Physical Team Test.

Teams will compete in male, female and mixed divisions, with awards recognizing individual challenges and overall performance. The annual competition also introduces high school cadets to the educational and leadership opportunities available through Florida Southern's Army ROTC program.

"Leadership is developed through experience, discipline and the willingness to push beyond perceived limits," said Lt. Col. Harry Dingle, professor of military science at Florida Southern College. "The Raider Competition gives young cadets an opportunity to put those principles into action. Lieutenant General Kerrick's remarkable career exemplifies that commitment to leadership and service, and his investment will help us continue developing future generations of leaders."

Established in 1951, Florida Southern's Army ROTC Moccasin Battalion has a longstanding tradition of preparing students for military service, with alumni including nine general officers and numerous distinguished military and civilian leaders.

The building dedication and statewide competition celebrate Kerrick's legacy of service while advancing the College's commitment to developing future leaders.

SOURCE Florida Southern College

Share this article

Luvme Hair Highlights Versatile Wig Looks for Fall 2026

The brand explores how different lengths, textures, and silhouettes can bring flexibility to seasonal hair styling.

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Luvme Hair is highlighting versatile wig looks for Fall 2026, focusing on the variety of lengths, textures, and silhouettes available to consumers looking to refresh their style for the changing season.

Rather than defining fall hair through a single aesthetic, Luvme Hair is placing greater emphasis on personal choice. From polished straight styles and soft waves to defined curls, layered cuts, and shorter silhouettes, different wig styles can offer distinct ways to approach seasonal dressing and everyday beauty routines.

Fall Styling Goes Beyond One Hair Trend

As temperatures change, wardrobes often shift toward sweaters, jackets, tailored layers, and richer seasonal colors. Hair can play a complementary role, with different textures and lengths creating new proportions and visual balance.

Luvme Hair's human hair wig includes a broad selection of straight, wavy, curly hair, textured, short, and longer styles. This variety allows wearers to consider their hairstyle alongside their daily routines, wardrobe preferences, and upcoming occasions.

For some, a sleek straight style can provide a polished finish for workdays. Others may prefer waves or curls that introduce movement and texture to a seasonal look. Shorter styles can create a more defined silhouette, while longer wigs offer additional opportunities for volume and styling.

Exploring Seasonal Looks Through Texture and Length

Texture can be just as influential as length when creating a fall-inspired appearance. Waves can add softness, curls can bring volume and movement, while straight textures can create a cleaner and more structured finish.

For shoppers interested in shorter seasonal styles, Luvme Hair's Fall Short Wig Hairstyles guide explores seven fall-ready looks, including dark plum waves, layered bobs, a soft pixie, cropped curls, and face-framing curls.

The brand's Short Wig collection provides another option for those who want to explore shorter silhouettes or pixie cut styles, while the Glueless Wig collection offers styles designed around a more convenient wearing experience.

From Everyday Routines to Seasonal Occasions

Fall styling can involve a wide range of settings, from workdays and casual weekends to dinners, gatherings, and upcoming holiday events. A versatile wig allows wearers to adjust their appearance according to the occasion without limiting themselves to one particular style direction.

For Luvme Hair, the Fall 2026 conversation is centered on flexibility rather than a single must-have look. Different lengths, textures, colors, and constructions give consumers more ways to approach their seasonal style while reflecting their individual preferences.

Whether the choice is a classic straight look, soft waves, defined curls, a layered silhouette, or a shorter cut, versatile wig styling gives fall wardrobes another way to evolve with the season.

About Luvme Hair

Luvme Hair offers human hair wigs across a range of textures, lengths, colors, and constructions, with a focus on natural-looking results, convenient wear, and versatile styling options for different routines and personal preferences.

Press Contact:

Jian Mei

[email protected]

shop.luvmehair.com/

SOURCE Luvme Hair

Share this article

Brightmoor Hospice, LLC Provides Notification of Data Security Incident

GRIFFIN, Ga., Oct. 16, 2026 /PRNewswire/ -- Brightmoor Hospice, LLC ("Brightmoor") is providing notification of a data security incident that may have impacted certain protected health information.

On or around March 25, 2026, Brightmoor Hospice, LLC ("Brightmoor") discovered suspicious activity related to two employees' email accounts. Upon discovery, Brightmoor took immediate action to secure the accounts and engaged a team of third-party specialists to investigate. The investigation determined that two employee email accounts were accessed without authorization between March 24, 2026, and March 25, 2026. Upon confirmation of unauthorized access, Brightmoor began a comprehensive review of the contents of the affected accounts to determine whether they contained sensitive information pertaining to individuals. On August 18, 2026, Brightmoor determined that protected health information belonging to certain patients was present within the accounts. Brightmoor then conducted a time-intensive review of its internal records to locate address information for the potentially impacted individuals. On October 16, 2026, Brightmoor began notifying individuals by mail.

The types of information vary by individual and may include name and one or more of the following: addresses, Social Security numbers, driver's license information, dates of birth, patients' identification numbers, diagnosis, medical history information, medical record numbers, medical treatment information, lab information, treating doctor's name, medication information, vaccination information, medical insurance information, and family and social history information.

In response to this incident, Brightmoor worked with third-party specialists to investigate and implement additional security measures within its network. Brightmoor has no evidence of actual or attempted misuse of information as a result of this incident. Nonetheless, in an abundance of caution, Brightmoor is providing notice to potentially affected individuals and offering complimentary credit monitoring services. Individuals are also encouraged to monitor their account statements and explanation of benefits forms for suspicious activity and to detect errors. In addition, Brightmoor has notified the U.S. Health and Human Services Office for Civil Rights of this incident.

Brightmoor has established a toll-free call center to answer questions about the incident and to address related concerns. The number for the hotline is 1-800-759-8524. The hotline hours of operation are Monday through Friday from 8 AM to 8 PM EST, excluding holidays. You can also write to 3247 Newnan Rd, Griffin, GA 30223.

Brightmoor takes protecting the privacy and security of personal information seriously and is reviewing and implementing further security enhancements designed to strengthen the protection of our systems.

SOURCE Brightmoor Hospice, LLC

Share this article

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.

Get Help

Chemours investors should visit us at https://claimsfiler.com/cases/nyse-cc-3/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."

On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

Share this article

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- - ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

Get Help

Hims & Hers investors should visit us at https://claimsfiler.com/cases/nyse-hims-1/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

(833) 538-3604

SOURCE ClaimsFiler

Share this article